GtoPdb Ligand ID: 7384

Synonyms: Blincyto® | bscCD19xCD3 | MEDI-538 | MT-103 | MT103 [2]
blinatumomab is an approved drug (FDA (2014), EMA (2015))
Compound class: Antibody
Comment: Blinatumomab is a monoclonal antibody with anti-cancer effects. Its mechanism of action classifies this antibody as a member of the bi-specific T-cell engager (BiTE®) group of engineered antibodies. It was the first biologic of this class to gain clinical approval.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Compound class Antibody
Approved drug? Yes (FDA (2014), EMA (2015))
International Nonproprietary Names
INN number INN
9028 blinatumomab
Blincyto® | bscCD19xCD3 | MEDI-538 | MT-103 | MT103 [2]
Database Links
Specialist databases
IMGT/mAb-DB 101
Other databases
GtoPdb PubChem SID 178103956
PubChem SID 178103956
Search PubMed clinical trials blinatumomab
Search PubMed titles blinatumomab
Search PubMed titles/abstracts blinatumomab
Wikipedia Blinatumomab